Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Aprepitant Injection for PONV Prevention
NCT06543966Phase 3Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Nausea and Vomiting comparing Aprepitant Injection with Placebo (2 arms). Primary endpoint: Complete response (CR) rates over 24 hours after the end of surgery. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NCT06543966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543966.